EVA1A and hepatocellular carcinoma: Additionally, hepatocellular carcinoma patients’ resistance to oxaliplatin treatment was linked to the downregulation of miR-125b, which was mediated via its target, EVA1A [84], thus illustrating how miR-125b regulates its target, EVA1A, to contribute to the possible mechanism of oxaliplatin resistance.